Publicacións (119) Publicacións de Jose Luis Fuster Soler

filter_list

2024

  1. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

    Journal of Neuro-Oncology, Vol. 166, Núm. 3, pp. 407-415

  2. Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression

    EMBO molecular medicine, Vol. 16, Núm. 1, pp. 64-92

  3. Clonal heterogeneity and genomic evolution in intrachromosomal amplification of chromosome 21: A case report

    British Journal of Haematology

  4. Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)

    Journal of Neuro-Oncology

  5. ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer

    Clinical and Translational Oncology, Vol. 26, Núm. 9, pp. 2351-2359

  6. Genetic and phenotypic findings in 34 novel Spanish patients with DDX3X neurodevelopmental disorder

    Clinical Genetics, Vol. 105, Núm. 2, pp. 140-149

  7. Haploidentical versus Cord Blood Transplantation in Pediatric AML. A Retrospective Outcome Analysis on Behalf of the Pediatric Subcommittee of GETH (Grupo Español de Trasplante Hematopoyético)

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1015.e1-1015.e13

  8. Hematopoietic stem cell transplantation in children with chronic granulomatous disease: the Spanish experience

    Frontiers in Immunology, Vol. 15

  9. Identification of copy-number variants in patients with overgrowth disorders

    Clinical Genetics, Vol. 106, Núm. 5, pp. 614-624

  10. Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

    HemaSphere, Vol. 8, Núm. 2

  11. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia

    Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 278-287

  12. Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Español de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee

    Cytotherapy